Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alexion Pharmaceuticals, Inc.
An open-label extension study to evaluate long-term safety of eculizumab in PNH patients who had completed the TRIUMPH (C04-001), SHEPHERD (C04-002), and X03-001 studies.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who have fully completed the TRIUMPH, SHEPHERD, or X03-001 studies
TRIUMPH patients who have discontinued receiving investigational drug prior to the last visit of the study due to lack of efficacy or exacerbation of symptoms of PNH and have completed all monthly safety and efficacy procedures
Patient must be willing and able to give written informed consent
Patient must avoid conception during the trial
You may not be if
Patients who have terminated early from the SHEPHERD or X03-001 studies
Patients who have terminated early from the TRIUMPH study due to an adverse event
Female who is pregnant, breast feeding, or intending to conceive during the course of the study
Any condition that could increase the patient's risk by participating in the study or could confound the outcome of the study
